Australia’s notifiable disease status, 2011: Annual report of the National Notifiable Diseases Surveillance System - Part 5

The National Notifiable Diseases Surveillance System monitors the incidence of an agreed list of communicable diseases in Australia. This report analyses notifications during 2011.

Page last updated: 26 May 2014

Appendices

Appendix 1: Mid-year estimate of Australian population, 2010, by state or territory
  State or territory  
  ACT NSW NT Qld SA Tas Vic. WA Aust
Source: Australian Bureau of Statistics 3101.0 Table 4. Estimated Resident Population, States and Territories. June 2011 population.6
Males
182,006
3,618,616
119,243
2,288,870
818,621
251,841
2,785,729
1,193,053
11,259,345
Females
183,615
3,683,558
111,126
2,291,412
837,678
258,678
2,835,481
1,156,272
11,358,949
Total
365,621
7,302,174
230,369
4,580,282
1,656,299
510,519
5,621,210
2,349,325
22,618,294

Top of page

Appendix 2: Mid-year estimate of Australian population, 2010, by state or territory and age
  State or territory  
Age group ACT NSW NT Qld SA Tas Vic. WA Aust
Source: Australian Bureau of Statistics 3201.0 Australian Demographic Statistics Tables. Jun 2011 population.6
0–4
24,753
462,145
18,596
316,938
99,846
33,654
358,023
158,329
1,472,401
5–9
21,588
445,890
17,342
293,467
94,291
31,242
333,625
145,446
1,383,048
10–14
21,056
450,244
16,811
299,077
99,255
32,798
335,769
149,972
1,405,184
15–19
24,028
475,159
16,615
314,120
107,459
34,580
362,670
157,551
1,492,373
20–24
31,424
524,682
18,529
334,507
116,656
32,218
424,247
176,077
1,658,472
25–29
32,519
542,391
21,012
338,319
113,523
29,422
431,998
181,711
1,691,066
30–34
29,103
511,983
18,986
309,727
103,279
28,108
401,641
164,792
1,567,777
35–39
27,155
514,410
18,282
323,148
107,375
31,719
401,750
166,709
1,590,705
40–44
25,906
502,205
17,238
323,844
115,013
34,619
403,868
170,951
1,593,846
45–49
25,078
502,570
16,056
316,883
116,426
35,855
386,759
166,010
1,565,859
50–54
24,008
484,798
14,842
300,064
114,784
37,091
367,255
155,889
1,498,929
55–59
21,103
435,632
12,546
269,824
105,590
34,843
330,426
140,104
1,350,263
60–64
18,858
403,654
9,784
251,795
99,883
33,078
304,100
125,789
1,247,102
65–69
12,945
314,996
5,975
192,330
76,706
25,733
233,011
91,071
952,868
70–74
9,233
244,764
3,645
141,270
59,995
19,526
183,133
69,327
730,961
75–79
6,689
190,584
1,917
102,982
47,754
14,654
143,602
51,640
559,851
80–84
5,069
153,094
1,192
79,058
40,124
11,217
115,327
39,330
444,422
85+
4,906
144,489
804
73,372
39,042
10,203
106,886
35,712
415,427
Total
365,421
7,303,690
230,172
4,580,725
1,657,001
510,560
5,624,090
2,346,410
22,620,554

Top of page

Appendix 3: Indigenous status, National Notifiable Diseases Surveillance System, Australia, 2011, by notifiable disease*
Disease name Aboriginal but not TSI origin TSI but not Aboriginal origin Aboriginal and TSI origin Not Indigenous Not stated Blank/ missing Total % complete Number complete Number incomplete
* Indigenous status is usually obtained from medical notification and completeness varies by disease and by state and territory. This reflects differences in notification requirements (i.e. depending on the jurisdiction, some diseases are primarily or completely notified by pathology laboratories rather than clinicians) and the fact that it is not possible to follow-up all cases for diseases with a large volume of notifications and/or not requiring specific case-based public health action. TSI Torres Strait Islander
Arbovirus infection (NEC)
0
0
0
20
4
0
24
86.5
20
4
Barmah Forest virus infection
37
8
1
623
810
391
1,870
62.4
669
1,201
Botulism
0
0
0
1
0
1
2
50.0
1
1
Brucellosis
0
0
0
23
16
0
39
86.7
23
16
Campylobacteriosis
200
24
16
9,070
8,148
259
17,717
52.3
9,310
8,407
Chlamydial infection
5,938
767
339
33,955
20,882
18,919
80,800
58.7
40,999
39,801
Cholera
0
0
0
2
4
0
6
60.0
2
4
Cryptosporidiosis
208
3
4
992
466
135
1,808
73.9
1,207
601
Dengue virus infection
3
1
1
663
123
26
817
83.1
668
149
Diphtheria
0
0
0
1
3
0
4
50.0
1
3
Gonococcal infection
4,045
345
145
3,705
1,688
2,159
12,087
79.1
8,240
3,847
Haemolytic uraemic syndrome
1
0
0
12
0
0
13
100.0
13
0
Haemophilus influenzae type b
2
0
0
11
0
0
13
100.0
13
0
Hepatitis A
1
0
1
133
9
0
144
95.9
135
9
Hepatitis B (newly acquired)
13
1
1
145
27
3
190
91.0
160
30
Hepatitis B (unspecified)
206
27
6
2,066
1,992
2,332
6,629
65.1
2,305
4,324
Hepatitis C (newly acquired)
67
0
0
287
39
7
400
91.2
354
46
Hepatitis C (unspecified)
550
12
23
3,156
3,497
2,623
9,861
55.9
3,741
6,120
Hepatitis D
1
0
0
32
2
8
43
70.6
33
10
Hepatitis E
0
0
0
37
3
0
40
93.2
37
3
Influenza (laboratory confirmed)
1,033
46
31
10,738
10,233
5,068
27,149
46.9
11,848
15,301
Kunjin virus infection
0
0
0
2
0
0
2
100.0
2
0
Legionellosis
6
0
0
307
30
5
348
87.8
313
35
Leprosy
0
0
0
8
0
0
8
100.0
8
0
Leptospirosis
9
1
0
164
42
1
217
95.1
174
43
Listeriosis
2
0
0
59
8
1
70
92.8
61
9
Malaria
1
9
2
334
59
6
411
91.7
346
65
Measles
10
0
0
173
8
2
193
93.6
183
10
Meningococcal disease (invasive)
22
2
0
206
11
0
241
97.5
230
11
Mumps
2
0
0
96
31
26
155
72.8
98
57
Murray Valley encephalitis virus infection
4
0
0
12
0
0
16
100.0
16
0
Ornithosis
0
0
0
76
6
3
85
75.1
76
9
Pertussis
673
55
61
18,771
12,515
6,527
38,602
68.4
19,560
19,042
Pneumococcal disease (invasive)
294
6
7
1,309
162
109
1,887
91.6
1,616
271
Q fever
11
0
1
239
75
12
338
89.0
251
87
Ross River virus infection
79
9
2
2,795
1,711
570
5,166
58.7
2,885
2,281
Rubella
1
0
0
44
7
6
58
76.1
45
13
Salmonellosis
360
15
17
5,915
2,976
2,984
12,267
70.8
6,307
5,960
Shigellosis
133
2
2
293
39
25
494
91.3
430
64
STEC, VTEC
2
0
0
85
5
3
95
92.3
87
8
Syphilis - congenital
3
0
0
3
0
0
6
100.0
6
0
Syphilis < 2 years
191
3
2
1,038
54
15
1,303
95.3
1,234
69
Syphilis > 2 years or unspecified duration
134
7
6
817
284
12
1,260
87.6
964
296
Tetanus
0
0
0
3
0
0
3
100.0
3
0
Tuberculosis
32
3
1
1,277
18
0
1,331
98.5
1,313
18
Tularaemia
0
0
0
2
0
0
2
100.0
2
0
Typhoid
0
0
0
127
6
1
134
90.5
127
7
Varicella zoster (chickenpox)†
145
4
0
1,727
206
12
2,094
76.3
1,876
218
Varicella zoster (shingles)†
110
3
1
3,349
504
32
3,999
73.7
3,463
536
Varicella zoster (unspecified)†
97
12
2
1,844
5,558
202
7,715
30.1
1,955
5,760
Yellow fever
0
0
0
1
1
0
2
50.0
1
1
Total
14,626
1,365
672
106,748
72,262
42,485
238,158
80.4
123,411
114,747

Top of page

References

  1. National Health Security Act, 2007. Accessed on November 2009. Available from: http://www.legislation.gov.au/Details/C2007A00174
  2. National Health Security (National Notifiable Disease List) Instrument. 2008. Accessed on. Available from: http://www.legislation.gov.au/ComLaw/legislation/LegislativeInstrument1.nsf/0/7162D634C6DD1BAACA25740B0079D6B8?OpenDocument
  3. National Health Security Agreement. 2008. Accessed on November 2009. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-nhs-agreement.htm
  4. The Kirby Institute. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report, 2012: The Kirby Institute, the University of New South Wales, Sydney; 2012.
  5. Klug GM, Boyd A, McGlade A, Stehmann C, Simpson M, Masters CL, et al. Surveillance of Creutzfeldt-Jakob disease in Australia: update to December 2011. Commun Dis Intell 2012;36(2):E174–E179.
  6. Australian Bureau of Statistics. Australian Demographic Statistics. Canberra: Australian Bureau of Statistics; 2011. Report No. 3101.0.
  7. Australian Institute of Health and Welfare. National Health Data Dictionary 13.3; 2008.
  8. Australian Government Department of Health and Ageing. National Hepatitis C Testing Policy; 2007.
  9. Medicare Australia. Australian Childhood Immunisation Register – Statistics. 2012. Accessed on 16 January 2013. Available from: http://www.medicareaustralia.gov.au/provider/patients/acir/statistics.jsp
  10. The Kirby Institute. National Blood-borne Virus and Sexually Transmissible Infections Surveillance and Monitoring Report 2011. Sydney, NSW: The Kirby Institute, the University of New South Wales; 2012.
  11. Butler T, Lim D, Callander D. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 and 2010. Prevalence of HIV, hepatitis C, hepatitis B, sexually transmissible infections, and risk behaviours among Australian prison entrants; 2011.
  12. Gidding HF, Warlow M, MacIntyre CR, Backhouse J, Gilbert GL, Quinn HE, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007;25(51):8637–8641.
  13. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007;91(2–3):228–235.
  14. Heymann DL. Control of Communicable Diseases Manual. 19th edn. Washington: American Public Health Association, USA; 2008.
  15. OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: Annual report of the OzFoodNet Network, 2010. Commun Dis Intell 2012;36(3):E213–E241.
  16. Donnan EJ, Fielding JE, Gregory JE, Lalor K, Rowe S, Goldsmith P, et al. A multistate outbreak of hepatitis A associated with semidried tomatoes in Australia, 2009. Clin Infect Dis 2012;54(6):775–781.
  17. Cumpston JHL. Health and disease in Australia. Canberra: Australian Government Publishing Service; 1989.
  18. Grattan-Smith PJ, O’Regan WJ, Ellis PS, O’Flaherty SJ, McIntyre PB, Barnes CJ. Rabies. A second Australian case with a long incubation period. Med J Aust 1992;156(9):651–654.
  19. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. History International Public Health 1988.

Top of page

  1. Australian Government Department of Health and Ageing. Guidelines for smallpox outbreak, preparedness, response and management. 2004. Accessed on. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/FD73F6A81331E729CA256F190004427D/$File/smallpox.pdf
  2. Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J, et al. Australia’s notifiable diseases status, 2003: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005;29(1):1–61.
  3. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2013. Accessed on. Available from: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html
  4. Curran M, Harvey B, Crerar S. Annual report of the National Notifiable Diseases Surveillance System, 1996. Commun Dis Intell 1997;21(20):281–307.
  5. Forssman B, Mannes T, Musto J, Gottlieb T, Robertson G, Natoli JD, et al. Vibrio cholerae O1 El Tor cluster in Sydney linked to imported whitebait. Med J Aust 2007;187(6):345–347.
  6. Chen MY, Fairley CK, Donovan B. Nowhere near the point of diminishing returns: correlations between chlamydia testing and notification rates in New South Wales. Aust N Z J Public Health 2005;29(3):249–253.
  7. Hocking J, Fairley C, Counahan M, Crofts N. The pattern of notification and testing for genital Chlamydia trachomatis infection in Victoria, 1998–2000: an ecological analysis. Aust N Z J Public Health 2003;27(4):405–408.
  8. Hammad A, Guy RJ, Fairley C, Wand H, Chen MY, Dickson B, et al. Understanding trends in genital Chlamydia trachomatis can benefit from enhanced surveillance: findings from Australia. Sex Transm Infect 2012;88(7):552–557.
  9. Australian Institute of Health and Welfare. Age-standardised rate – Identifying and definitional attributes. 2005. Accessed on 17 March 2010. Available from: http://meteor.aihw.gov.au/content/index.phtml/itemId/327276
  10. Stephens N, O’Sullivan M, Coleman D, Shaw K. Chlamydia trachomatis in Tasmania 2001–2007: rising notification trends. Aust N Z J Public Health 2010;34(2):120–125.
  11. Hammerschlag M. Sexually transmitted diseases in sexually abused children: medical and legal implications. Sex Transm Infect 1998;74(3):167–174.
  12. World Health Organization. Sexually transmitted infection: Chlamydia trachomatis. 2013. Accessed on 17 January 2013. Available from: http://www.who.int/vaccine_research/diseases/soa_std/en/index1.html
  13. Graham S, Guy RJ, Donovan B, McManus H, El-Hayek C, Kwan K, et al. Epidemiology of chlamydia and gonorrhea among Indigenous and non-Indigenous Australians, 2000–2009. Med J Aust 2012;197(11):642–646.
  14. Department of Health Victoria. Infectious diseases epidemiology and surveillance: donovanosis. 2007. Accessed on 17 January 2013. Available from: http://ideas.health.vic.gov.au/bluebook/donovanosis.asp
  15. Bowden FJ, on behalf of the National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going... Sex Transm Infect 2005;81(5):365–366.
  16. Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2011. Commun Dis Intell 2012;36(2):E166–E173.
  17. Government of Western Australia. Department of Health. The Epidemiology of Notifiable Sexually Transmitted Infections and Blood-Borne Viruses in Western Australia 2009. Perth: Department of Health, Western Australia; 2010.
  18. Ward J, Guy RJ, Akre S, Middleton M, Giele C, Su J, et al. Epidemiology of syphilis in Australia: moving toward elimination of infectious syphilis from Aboriginal and Torres Strait Islander communities? Med J Aust 2011;194(10):525–529.
  19. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine Preventable Diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
  20. Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H, et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006–2010. Commun Dis Intell 2013;37(Suppl):S1–S95.

Top of page

  1. Gidding HF, Backhouse JL, Burgess MA, Gilbert GL. Immunity to diphtheria and tetanus in Australia: a national serosurvey. Med J Aust 2005;183(6):301–304.
  2. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, et al. General practice activity in Australia 2009–10. Canberra: Australian Institute of Health and Welfare; 2010.
  3. Virginia Polytechnic Institute and State University. Why is the flu more common during the winter season? ScienceDaily 2012.
  4. Australian Government Department of Health and Ageing. Immunise Australia Program—Pneumococcal disease. 2012. Accessed on 4 January 2013. Available from: www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-pneumococcal
  5. Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health and Ageing; 2013.
  6. Rosewell A, Reinten-Reynolds T, Spokes P. Measles in NSW, 2002–2011. N S W Public Health Bull 2012;23(9–10):201–207.
  7. Gidding H, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long-term maintenance. Vaccine 2007;25:3574–3580.
  8. Gidding HF, Gilbert GL. Measles immunity in young Australian adults. Commun Dis Intell 2001;25(3):133–136.
  9. World Health Organization. Monitoring progress towards measles elimination. Wkly Epidemiol Rec 2010;85:490–494.
  10. Heywood AE, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly HA. Elimination of endemic measles transmission in Australia. Bull World Health Organ 2009;87(1):64–71.
  11. Gay NJ, De Serres G, Farington P, Redd SB, Papania MJ. Assessment of the status of measles elimination from reported outbreaks: United States, 1997–1999. J Infect Dis 2004;189(Suppl 1):S36–S42.
  12. Rosewell A, Spokes P, Gilmour R. NSW annual vaccine-preventable disease report, 2011. N S W Public Health Bull 2012;23(9–10):171–178.
  13. Stein-Zamir C, Shoob H, Abramson N, Tallen-Gozani E, Sokolov I, Zentner G. Mumps outbreak in Jerusalem affecting mainly male adolescents. Euro Surveill 2009;14(50):pii:19440.
  14. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 2007;13(1):12–17.
  15. Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the “forgotten” age group in 1998 Australian Measles Control Campaign. Med J Aust 2008;189(8):4.
  16. Quinn H, McIntyre PB. Impact of removal of the 18 month DTPa dose on pertussis vaccine effectiveness. In: 12th National Immunisation Conference. Adelaide, South Australia; 2010.
  17. Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58–S61.
  18. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995–2005 – trends by region and age group. Commun Dis Intell 2007;31(2):205–215.
  19. Georgousakis M, Quinn H, Wang H, Snelling T, Macartney K, McIntyre P. Pertussis deaths in Australia—what has changed? In: 13th National Immunisation Conference. Darwin Convention Centre, Darwin NT: Public Health Association Australia; 2012.
  20. Munoz FM. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006;17(1):14–19.

Top of page

  1. Marshall H. Severity of disease in children hospitalised with pertussis infection during an epidemic [abstract]. In: Public Health Association of Australia, editor. Communicable Disease Control Conference 2011; Science and Public Health meeting the challenges of a new decade. Canberra; 2011. p. 58.
  2. Quinn HE, Mahajan D, Hueston L, Campbell P, Menzies RI, Gilbert GL, et al. The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules. N S W Public Health Bull 2011;22(11–12):224–229.
  3. Kaczmarek M, Lambert S, Kelly H, Ware R, Valenti L, Britt H. Seven-fold rise in likelihood of pertussis-test requests during Australian GP encounters, 2000–2011. In: 13th National Immunisation Conference. Darwin Convention Centre, Darwin, Northern Territory: Public Health Association of Australia; 2012.
  4. Misegades L, Winter K, Harriman K, Talarico J, Messonnier NE, Clark T, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012;308(20):2126–2132.
  5. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013;131(4):e1047–e1052.
  6. Sheridan S, Ware R, Grimwood K, Lambert S. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012;308(5):454–456.
  7. Quinn HE. Pertussis vaccine effectiveness in Australia [abstract]. In: National pertussis workshop: strategies to prevent severe pertussis in the next decade. Sydney Australia: National Centre for Immunisation and reseaarch of Vaccine Preventable Diseases Newsletter; 2011.
  8. Octavia S, Sintchenko V, Gilbert G, Lawrence A, Keil A, Hogg G, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008–2010. J Infect Dis 2012;205(8):1220–1224.
  9. Australian Technical Advisory Group on Immunisation. Bulletin 44th meeting 24–25 February 2011.
  10. Australian Technical Advisory Group on Immunisation. Bulletin 46th meeting 13–14 October 2011.
  11. Knope K, Whelan P, Smith D, Johansen C, Moran R, Doggett S, et al. Arboviral diseases and malaria in Australia, 2010–11: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell 2013;37(1):E1–E20.
  12. Mackenzie JS, Lindsay MD, Coelen RJ, Broom AK, Hall RA, Smith DW. Arboviruses causing human disease in the Australasian zoogeographic region. Arch Virol 1994;136:447–467.
  13. Russell RC, Dwyer DE. Arboviruses associated with human disease in Australia. Microbes Infect 2000;2(14):1693–1704.
  14. Viennet E, Knope K, Faddy HM, Williams CR, Harley D. Assessing the threat of chikungunya virus emergence in Australia. Commun Dis Intell 2013;37(2):E136–E143.
  15. Communicable Diseases Network Australia. Australian national notifiable diseases case definitions. 2011. Accessed on 4 August 2011. Available from: http://www.health.gov.au/casedefinitions
  16. Roche SE, Wicks R, Garner MG, East IJ, Paskin R, Moloney BJ, et al. Descriptive overview of the 2011 epidemic of arboviral disease in horses in Australia. Aust Vet J 2013;91(1–2):5–13.
  17. Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987;21(3):270–279.
  18. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181(1):2–9.
  19. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004;10(12 Suppl):S98–S109.
  20. Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, et al. Dengue in north Queensland, 2005–2008. Commun Dis Intell 2009;33(2):198–203.

Top of page

  1. Queensland Health. Queensland Dengue Management Plan 2010–2015, 2011. Queensland: Queensland Health.
  2. Knope K, National Arbovirus and Malaria Advisory Committee, Giele, C. Increasing notifications of dengue related to overseas travel, 1991 to 2012. Commun Dis Intell 2013;37(1):E55–E59.
  3. Ritchie S. Outbreaks of dengue in North Queensland. In; 2012.
  4. Clark B, Molton J, Habib T, Williams D, Weston E, Smith D. Dengue virus infection in Australia following occupational exposure: A reflection of increasing numbers of imported cases. J Clin Virol 2012;54(4):376–377.
  5. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46(2):165–171.
  6. Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS, Barnett E, et al. Travel-associated illness trends and clusters, 2000–2010. Emerg Infect Dis 2013;19(7):1049–1073.
  7. World Health Organization. Synopsis of the world malaria situation in 1981. Wkly Epidemiol Rec 1983;58(26):197–199.
  8. Gray TJ, Trauer JM, Fairley M, Krause VL, Markey PG. Imported malaria in the Northern Territory, Australia—428 consecutive cases. Commun Dis Intell 2012;36(1):107–113.
  9. Preston-Thomas A, Gair RW, Hosking KA, Devine GJ, Donohue SD. An outbreak of Plasmodium falciparum malaria in the Torres Strait. Commun Dis Intell 2012;36(2):E180–E185.
  10. Hanna JN, Ritchie SA, Eisen DP, Cooper RD, Brookes DL, Montgomery BL. An outbreak of Plasmodium vivax malaria in Far North Queensland, 2002. Med J Aust 2004;180(1):24–28.
  11. World Health Organization. Zoonoses. Technical report series no. 169. Geneva, Switzerland: World Health Organization; 1959.
  12. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 2001;356(1411):983–989.
  13. Jones KE, Patel NG, Levy MA. Global trends in emerging infectious diseases. Nature 2008(451):990–994.
  14. Woolhouse MEJ, Gowtage-Sequeria S. Host range and emerging and reemerging pathogens. Emerg Infect Dis 2005;11(12):1842–1847.
  15. World Health Organization. Report of the WHO/FAO/OIE joint consultation on emerging zoonotic diseases. Geneva, Switzerland: World Health Organization; 2004.
  16. Animal Health Australia. Animal Health in Australia 2012. Canberra; 2013.
  17. NSW Department of Health. Communicable Diseases Report, NSW, January and February 2010. N S W Public Health Bull 2010;21(3–4):103–107.
  18. Kolbe A, Yuen M, Doyle B. A case of human cutaneous anthrax. Med J Aust 2006;185(5):281–282.
  19. Fielding J. Zoonoses: Anthrax. Vic Infect Dis Bull 2007;10(2):47.
  20. Animal Health Australia. Animal Health in Australia 2011. Canberra; 2012.

Top of page

  1. Calisher CH, Ellison JA. The other rabies viruses: The emergence and importance of lyssaviruses from bats and other vertebrates. Travel Med Infect Dis 2012;10(2):69–79.
  2. Fraser GC, Hooper PT, Lunt RA, Gould AR, Gleeson LJ, Hyatt AD, et al. Encephalitis caused by a lyssavirus in fruit bats in Australia. Emerg Infect Dis 1996;2(4):327–331.
  3. Hooper PT, Lunt RA, Gould AR, Samaratunga H, Hyatt AD, Gleeson LJ, et al. A new lyssavirus—the first endemic rabies-related virus recognized in Australia. Bulletin de l’Institut Pasteur 1997;95(4):209–218.
  4. Communicable Diseases Network Australia. Series of National Guidelines: Rabies virus and other lyssavirus including Australian bat lyssavirus) exposures and infections. 2013. Accessed on 7 June 2013. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-abvl-rabies.htm
  5. Allworth A, Murray K, Morgan J. A human case of encephalitis due to a lyssavirus recently identified in fruit bats. Commun Dis Intell 1996;20(24):504.
  6. Hanna JN, Carney IK, Smith GA, Tannenberg AEG, Deverill JE, Botha JA, et al. Australian bat lyssavirus infection: a second human case, with long incubation period. Med J Aust 2000;172(12):597–599.
  7. Francis JR, Nourse C, Vaska VL, Calvert S, Northill JA, McCall B, et al. Australian bat lyssavirus in a child: The first reported case. Pediatrics 2014;133(4):e1063–1067.
  8. Queensland Department of Agriculture Fisheries and Forestry. Australian bat lyssavirus veterinarian communiqué, 21 May 2013. Accessed on 7 July 2013. Available from: http://www.vsbsa.org.au/images/File/ABLV%20vet%20communique%2021%20May%202013.pdf
  9. Queensland Department of Agriculture Fisheries and Forestry. Australian bat lyssavirus update communiqué 7 June 2013. Accessed on 7 July 2013. Available from: http://www.ava.com.au/sites/default/files/Lyssavirus%20communique%20130607.pdf
  10. Australian Bat Lyssavirus Focus Group. Australian bat lyssavirus report, December 2011: Australian Wildlife Health Network; 2011.
  11. Eales KM, Norton RE, Ketheesan N. Brucellosis in northern Australia. Am J Trop Med Hyg 2010;83(4):876–878.
  12. World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. Geneva, Switzerland: World Health Organization; 2003.
  13. Levett PN. Leptospirosis. Clin Microbiol Rev 2001;14(2):296–326.
  14. O’Leary FM, Hunjan JS, Bradbury R, Thanakrishnan G. Fatal leptospirosis presenting as musculoskeletal chest pain. Med J Aust 2004;180(1):29–31.
  15. Smith JK, Young MM, Wilson KL, Craig SB. Leptospirosis following a major flood in Central Queensland, Australia. Epidemiol Infect 2012;141(3):1–6.
  16. Queensland Health. Statewide Weekly Communicable Diseases Surveillance Report, 4 April 2011: Epidemiology, Surveillance and Research Unit; 2011.
  17. Beeckman DS, Vanrompay DC. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol Infect 2009;15(1):11–17.
  18. Deschuyffeleer TP, Tyberghien LF, Dickx VL, Geens T, Saelen JM, Vanrompay DC, et al. Risk assessment and management of Chlamydia psittaci in poultry processing plants. Ann Occup Hyg 2012;56(3):340–349.
  19. Department of Health Victoria. Communicable disease surveillance October–December 2011. Victorian Infectious Diseases Bulletin 2012;15(1):21–39.
  20. McCaul TF, Williams JC. Developmental cycle of Coxiella burnetii: structure and morphogenesis of vegetative and sporogenic differentiations. J Bacteriol 1981;147(3):1063–1076.
  21. Lowbridge CP, Tobin S, Seale H, Ferson MJ. Notifications of Q fever in NSW, 2001–2010. N S W Public Health Bull 2012;23(1–2):31–35.
  22. Bell M, Patel M, Sheridan J. Q fever vaccination in Queensland abattoirs. Commun Dis Intell 1997;21(3):29–31.
  23. Lin M, Delpech V, McAnulty J, Campbell-Lloyd S. Notifications of Q fever in New South Wales, 1991–2000: EpiReview. N S W Public Health Bull 2001;12(6):172–175.
  24. Gidding HF, Wallace C, Lawrence G, McIntyre PB. Australia’s National Q Fever Vaccination Program. Vaccine 2009;27(14):2037–2041.
  25. NNDSS Annual Report Writing Group. Australia’s notifiable disease status, 2010: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2012;36(1):1–69.
  26. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev 2002;15(4):631–646.
  27. Jackson J, McGregor A, Cooley L, Ng J, Brown M, Ong CW, et al. Francisella tularensis subspecies holarctica, Tasmania, Australia, 2011. Emerg Infect Dis 2012;18(9):1484–1486.
  28. Veitch M. The public health response to tularemia in Tasmania. In: Communicable Disease Control (CDC) Conference 2013. Canberra, Australia; 2013.
  29. Lahra MM, Enriquez RP. Australian Meningoccal Surveillance Programme annual report, 2012. Commun Dis Intell 2013;37(3):E224–E232.

In this section

CDI Search

Search Communicable Diseases Intelligence

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

Communicable Diseases Surveillance

Communicable Diseases Intelligence